RU2018130106A - Вакцина против синтетических опиоидов - Google Patents
Вакцина против синтетических опиоидов Download PDFInfo
- Publication number
- RU2018130106A RU2018130106A RU2018130106A RU2018130106A RU2018130106A RU 2018130106 A RU2018130106 A RU 2018130106A RU 2018130106 A RU2018130106 A RU 2018130106A RU 2018130106 A RU2018130106 A RU 2018130106A RU 2018130106 A RU2018130106 A RU 2018130106A
- Authority
- RU
- Russia
- Prior art keywords
- vaccine
- drug
- group
- fentanyl
- patient
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 8
- 229940005483 opioid analgesics Drugs 0.000 title 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical group C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 6
- 229960002428 fentanyl Drugs 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- 229940098773 bovine serum albumin Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229960000814 tetanus toxoid Drugs 0.000 claims 2
- 208000003870 Drug Overdose Diseases 0.000 claims 1
- 206010033296 Overdoses Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 231100000725 drug overdose Toxicity 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 231100000636 lethal dose Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281262P | 2016-01-21 | 2016-01-21 | |
| US62/281,262 | 2016-01-21 | ||
| PCT/US2017/013865 WO2017127390A1 (en) | 2016-01-21 | 2017-01-18 | Synthetic opioid vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018130106A true RU2018130106A (ru) | 2020-02-21 |
| RU2018130106A3 RU2018130106A3 (enExample) | 2020-05-26 |
Family
ID=59362842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018130106A RU2018130106A (ru) | 2016-01-21 | 2017-01-18 | Вакцина против синтетических опиоидов |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11305010B2 (enExample) |
| EP (1) | EP3405475B1 (enExample) |
| JP (1) | JP2019506390A (enExample) |
| CN (1) | CN108884127A (enExample) |
| BR (1) | BR112018014908A2 (enExample) |
| RU (1) | RU2018130106A (enExample) |
| WO (1) | WO2017127390A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019094528A1 (en) | 2017-11-09 | 2019-05-16 | The Scripps Research Institute | An improved heroin vaccine |
| WO2020006563A1 (en) * | 2018-06-29 | 2020-01-02 | Marquette University | Fluorinated compounds as ph-sensitive analgesics |
| WO2021092446A1 (en) * | 2019-11-08 | 2021-05-14 | Regents Of The University Of Minnesota | Fentanyl hapten, fentanyl hapten-conjugates, and methods for making and using |
| US20230100186A1 (en) * | 2020-01-13 | 2023-03-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Fentanyl haptens for the preparation of a fentanyl vaccine |
| WO2021183913A1 (en) * | 2020-03-13 | 2021-09-16 | Regents Of The University Of Minnesota | Fentanyl haptens, fentanyl hapten conjugates, and methods for making and using |
| US20240307517A1 (en) * | 2021-05-10 | 2024-09-19 | Cornell University | Development of a highly efficient second generation fentanyl-conjugate vaccine to treat fentanyl addiction |
| WO2024215826A2 (en) * | 2023-04-13 | 2024-10-17 | Avicenna Biotech Research, Llc | Compositions and methods for treating fentanyl dependence |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283066A (en) * | 1992-02-19 | 1994-02-01 | Development Center For Biotechnology | Method of stimulating an immune response by using a hapten |
| JPH07505634A (ja) | 1992-04-06 | 1995-06-22 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | 新規オピエート誘導体，タンパクおよびポリペプチドオピエート誘導共役体および標識 |
| US6262265B1 (en) | 1999-06-18 | 2001-07-17 | Microgenics Corporation | Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay |
| ES2284783T3 (es) * | 2001-11-16 | 2007-11-16 | Randox Laboratories Ltd. | Metodo y estuche para detectar, o determinar la cantidad de,metabolitos de fentanilo y metabolitos de analogos de fentanilo. |
| KR101228376B1 (ko) * | 2002-07-18 | 2013-01-31 | 사이토스 바이오테크놀로지 아게 | 합텐-캐리어 컨쥬게이트 및 그의 용도 |
| WO2004111202A2 (en) * | 2003-03-07 | 2004-12-23 | Incyte Corporation | Neurotransmission-association proteins |
| MXPA04006617A (es) | 2004-07-07 | 2006-01-12 | Inst Nac De Psiquiatria Ramon | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
| EP1850873B1 (en) * | 2005-02-08 | 2018-11-28 | Genzyme Corporation | Antibodies to tgfbeta |
| US20110182918A1 (en) * | 2008-06-13 | 2011-07-28 | Nabi Biopharmaceuticals | Personalized drug treatment and smoking cessation kit and method |
| US9296802B2 (en) * | 2009-04-15 | 2016-03-29 | Postech Academy-Industry Foundation | Target-specific non-antibody protein and method for preparing the same |
| CA2818548A1 (en) * | 2010-11-19 | 2012-05-24 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
| CA2857645A1 (en) * | 2011-11-30 | 2013-06-06 | Wellstat Diagnostics, Llc | Assays, antibodies, immunogens and compositions related to 5-fu |
| US20150343054A1 (en) | 2011-12-21 | 2015-12-03 | Kim D. Janda | Heroin Haptens, Immunoconjugates and Related Uses |
| US20140093525A1 (en) | 2012-09-17 | 2014-04-03 | Minneapolis Medical Research Foundation | Compositions and methods of treating opioid addiction |
| WO2014124317A1 (en) | 2013-02-08 | 2014-08-14 | Regents Of The University Of Minnesota | Analgesic conjugates |
| US9213029B2 (en) * | 2013-06-25 | 2015-12-15 | Samsung Electronics Co., Ltd. | Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients |
-
2017
- 2017-01-18 EP EP17741829.0A patent/EP3405475B1/en active Active
- 2017-01-18 WO PCT/US2017/013865 patent/WO2017127390A1/en not_active Ceased
- 2017-01-18 BR BR112018014908-0A patent/BR112018014908A2/pt not_active Application Discontinuation
- 2017-01-18 US US16/071,199 patent/US11305010B2/en active Active
- 2017-01-18 CN CN201780007832.8A patent/CN108884127A/zh active Pending
- 2017-01-18 JP JP2018537799A patent/JP2019506390A/ja active Pending
- 2017-01-18 RU RU2018130106A patent/RU2018130106A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210128720A1 (en) | 2021-05-06 |
| JP2019506390A (ja) | 2019-03-07 |
| WO2017127390A1 (en) | 2017-07-27 |
| RU2018130106A3 (enExample) | 2020-05-26 |
| BR112018014908A2 (pt) | 2018-12-18 |
| CN108884127A (zh) | 2018-11-23 |
| EP3405475A4 (en) | 2019-08-28 |
| CA3015336A1 (en) | 2017-07-27 |
| US11305010B2 (en) | 2022-04-19 |
| EP3405475A1 (en) | 2018-11-28 |
| EP3405475B1 (en) | 2022-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018130106A (ru) | Вакцина против синтетических опиоидов | |
| JP2019506390A5 (enExample) | ||
| KR940003057B1 (ko) | 경구적(Oral) 전달방법 | |
| CY1118373T1 (el) | Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος | |
| RU2010107207A (ru) | Новые синтетические агонисты tlr9 | |
| Crouse et al. | A TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models | |
| Coban et al. | The malarial metabolite hemozoin and its potential use as a vaccine adjuvant | |
| CN103768595B (zh) | 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗 | |
| SE0301663D0 (sv) | Analysmetod för infusionsläkemedel | |
| US20070231344A1 (en) | Conjugate vaccines for non-proteinaceous antigens | |
| Jacob et al. | Investigations of enantiopure nicotine haptens using an adjuvanting carrier in anti-nicotine vaccine development | |
| CU23917B1 (es) | Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína | |
| CN104623654A (zh) | 壳寡糖的应用及含壳寡糖的疫苗剂 | |
| EA201390181A1 (ru) | Несущий корпус для лекарственного средства и способ его изготовления | |
| CN101972477B (zh) | 磷酸锌疫苗佐剂 | |
| US10487141B2 (en) | Enantiopure haptens for nicotine vaccine development | |
| CN104096229A (zh) | 甘氨酸锌佐剂及含甘氨酸锌佐剂的疫苗 | |
| CN104056266A (zh) | 新喋呤佐剂及含新喋呤佐剂的疫苗 | |
| CN104667272A (zh) | 一种动物免疫佐剂及其制备方法和使用方法 | |
| CN102085366B (zh) | 一种复合疫苗佐剂 | |
| CN103736090A (zh) | 甲磺酸去铁胺佐剂及含甲磺酸去铁胺佐剂的疫苗 | |
| WO2007131017A3 (en) | A METHOD FOR DELIVERING A HUMAN CHORIONIC GONADOTROPIN (hCG) VACCINE FOR LONG-ACTING ANTIBODY PRODUCTION | |
| UA26447U (en) | Method for producing immune sera | |
| RU2012128562A (ru) | Способ пролонгированного обезболивания в раннем послеоперационном периоде у больных геморроем iii-iv стадий | |
| TH85786B (th) | กรรมวิธีสำหรับการเตรียมและการใช้ไบลาเลนซ์วัตซีนต่อการการติดมอร์ฟีน-เอโรอีน |